Medscape www.medscape.com

References for:
Hyperbilirubinemia in Term and Near-Term Infants: Kernicterus on the Rise?

[NBIN 4(4):191-200, 2004. © 2004 W.B. Saunders]

  1. Hsia DY, Allen FH, Gellis SS. Erythroblastosis fetalis. VIII. Studies of serum bilirubin in relation to kernicterus. N Engl J Med 1952;247:668-671.
  2. Mollison PL, Walker W. Controlled trials of the treatment of haemolytic disease of the newborn. Lancet 1952;1:429-433.
  3. Hansen TW. Kernicterus: An international perspective. Semin Neonatol 2002;7:103-109.
  4. Davidson L, Thilo EH. How to make kernicterus a "never event". NeoReviews 2003;4:e308. Accessed on November 15, 2003. URL: http://www.neoreviews.aappublications.org.
  5. Newman TB, Maisels MJ. Evaluation and treatment of jaundice in the term newborn: A kinder, gentler approach. Pediatrics 1992;89:809-818.
  6. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Practice parameter: Management of hyperbilirubinemia in the healthy term newborn. Pediatrics 1994;94:558-562.
  7. Brown AK. Kernicterus: Past, present and future. NeoReviews 2003;4:e33. Accessed on November 15, 2003. URL: http://www.neoreviews.aappublications.org.
  8. Joint Commission on Accreditation of Healthcare Organizations. Kernicterus threatens healthy newborns. Sentinel Event Alert 2001;. Accessed on November 22, 2003. URL: http://www.jcaho.org.
  9. Kernicterus in full-term infants: United States, 1994-1998. Morbid Mortal Wkly Rev 2001;50:491-494. Accessed on October 18, 2004. URL: http://www.cdc.gov.
  10. MacMahon JR, Stevenson DK, Oski FA. Bilirubin metabolism. In Avery's Diseases of the Newborn, eds Taeusch HW, Ballard RA. Philadelphia, PA: Saunders; 1998. 995-1002.
  11. Maisels MJ. Jaundice. In Neonatology: Pathophysiology and Management of the Newborn, eds Avery GB, Fletcher MA, MacDonald MG. Philadelphia, PA: Lippincott; 1999. 765-819.
  12. MacMahon JR, Stevenson DK, Oski FA. Physiologic jaundice. In Avery's Diseases of the Newborn, eds Taeusch HW, Ballard RA. Philadelphia, PA: Saunders; 1998. 1002-1007.
  13. Porter ML, Dennis MC. Hyperbilirubinemia in the term newborn. Am Fam Physician 2002;. Accessed on November 10, 2003. URL: http://www.aafp.org.
  14. Stevenson DK, Fanaroff AA, Maisels JM. Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics 2001;108:31-39.
  15. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: A worldwide potential cause of severe neonatal hyperbilirubinemia. NeoReviews 2000;1:e32-e39. Accessed on November 22, 2003. URL: http://www.neoreviews.aappublications.org.
  16. Kaplan M, Hammerman C. Glucose-6-phosphate deficient neonates: A potential cause for concern in North America. Pediatrics 2000;106:1478-1480.
  17. Reiser D. Hyperbilirubinemia. Lifelines 2001;5:55-61.
  18. Brown AK, Johnson L. Loss of concern about jaundice and the reemergence of kernicterus in full-term infants in the era of managed care. In Yearbook of Neonatal and Perinatal Medicine, eds Fanaroff AA, Klaus MK. St Louis, MO: Mosby; 1996. xvii-xxviii.
  19. AAP Subcommittee on Neonatal Hyperbilirubinemia. Neonatal jaundice and kernicterus. Pediatrics 2001;108:763-765.
  20. Gourley GR. Breast-feeding, neonatal jaundice and kernicterus. Semin Neonatol 2002;7:137-141.
  21. Bhutani VK, Johnson LH. Kernicterus: Lessons for the future from a current tragedy. NeoReviews 2003;4:e30. Accessed on November 11, 2003. URL: http://www.neoreviews.aappublications.org.
  22. Bratid D. How bilirubin gets into the brain. Clin Perinatol 1990;17:449-468.
  23. Wennberg RP. The blood-brain barrier and bilirubin encephalopathy. Cell Mol Neurobiol 2000;20:97-109.
  24. Watchko JF, Daood MJ, Biniwale M. Understanding neonatal hyperbilirubinaemia in the era of genomics. Semin Neonatol 2002;7:143-152.
  25. MacMahon JR, Stevenson DK, Oski FA. Bilirubin toxicity, encephalopathy, and kernicterus. In Avery's Diseases of the Newborn, eds Taeusch HW, Ballard RA. Philadelphia, PA: Saunders; 1998. 1008-1013.
  26. McConaguh AF, Chem C. Is bilirubin good for you? Clin Perinatol 1990;17:359-369.
  27. Stocker R, Yamamoto Y, McConaguh AF. Bilirubin is an antioxidant of possible physiologic importance. Science 1987;235:1043-1046.
  28. Maisels MJ, Newman TB. Kernicterus in otherwise healthy, breastfed term newborns. Pediatrics 1995;96:730-733.
  29. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency: A potential source of severe neonatal hyperbilirubinaemia and kernicterus. Semin Neonatol 2002;7:121-128.
  30. Dennery PA, Seidman DS, Stevenson DK. Neonatal hyperbilirubinemia. N Engl J Med 2001;344:581-590.
  31. Evidence Report/Technology Assessment: Number 65: Management of neonatal hyperbilirubinemia. Agency for Healthcare Research and Quality 2002;. Accessed on September 14, 2003. URL: http://www.ahcpr.gov.
  32. Rubaltelli FF, Courley GR, Loskamp NL. Transcutaneous bilirubin measurement: A multicenter evaluation of a new device. Pediatrics 2001;107:1264-1270.
  33. Richmond G, Brown M, Wagstaff P. Using a home care model to monitor bilirubin levels in early discharged infants. Topics in Health Information Management 2003;24:39-41.
  34. Vreman HJ, Wong RJ, Harmatz P. Validation of the natus co-statTend tidal breath analyzer in children and adults. J Clin Monitor Comput 1999;15:421-427.
  35. Herschel M, Karrison T, Wen M. Evaluation of the direct antiglobulin (Coombs') test for identifying newborns at risk for hemolysis as determined by end-tidal carbon monoxide concentration (ETCO2c); and comparison of the Coombs test with ETCOc for detecting significant jaundice. J Perinatol 2001;22:341-347.
  36. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term infants. Pediatrics 1999;103:6-14.
  37. Kaplan M, Hammerman C, Feldman R. Predischarge bilirubin screening in glucose-6-phosphate dehydrogenase-deficient neonates. Pediatrics 2000;105:533-537.
  38. Chou SC, Palmer RH, Ezhuthachian S. Management of hyperbilirubinemia in newborns: Measuring performance by using a benchmarking model. Pediatrics 2003;112:1264-1273.
  39. Hammerman C, Kaplan M. Recent developments in the management of neonatal hyperbilirubinemia. NeoReviews 2000;1:e19-e24. Accessed on November 22, 2003. URL: http://www.neoreviews.aappublications.org.
  40. Gartner LM. Breastfeeding and jaundice. J Pediatr 2001;21:s21-s29.
  41. Dennery PA. Pharmacological interventions for the treatment of neonatal jaundice. Semin Neonatol 2002;7:111-119.
  42. Hansen TW, Tommarello S. Effect of phenobarbital on bilirubin metabolism in rat brain. Biol Neonate 1998;73:106-111.
  43. Li Bu, Whittington PF, Odell GB. The reversal of bilirubin-induced intestinal secretion by agar. Pediatr Res 1984;18:79-82.
  44. Nicolopoulos D, Hadjigeorgiou E, Malamitsi A. Combined treatment of neonatal jaundice with cholestyramine and phototherapy. J Pediatr 1978;93:684-688.
  45. Rubo J, Albrect K, Lasch P. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh disease. J Pediatr 1992;21:93-97.
  46. Hammerman C, Breman HG, Kaplan M. Intravenous immune globulin in neonatal immune hemolytic disease: Does it reduce hemolysis? Acta Paediatr Scand 1996;85:1351-1353.
  47. Hammerman C, Kaplan M, Vreman H. Intravenous immune globulin in neonatal ABO isoimmunization: Factors associated with clinical efficacy. Biol Neonate 1996;70:69-74.
  48. Alcock GS, Liley H. Immunoglobulin infusion for haemolytic jaundice in neonates. Cochrane Library 2003;. Accessed on January 10, 2004. URL: http://www.nichd.nih.gov/cochraneneonatal.
  49. Kappas AK. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin. Pediatrics 2004;113:119-123.
  50. Anderson KE, Simionatto CS, Drummond GS. Disposition of tin-protoporphyrin and suppression of hyperbilirubinemia in humans. Clin Pharmacol Ther 1986;39:510-520.
  51. Kappas A, Drummond GS, Valaes T. A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient newborns. Pediatrics 2001;108:25-30.
  52. Kappas A, Munson DP, Marshall JR. Sn-mesoporphyrin interdiction of severe hyperbilirubinemia in Jehovah's Witness newborns as an alternative to exchange transfusion. Pediatrics 2001;108:1374-1377.
  53. Martinez JC, Garcia HO, Otherguy LE. Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin. Pediatrics 1999;103:1-5.
  54. Kappas A, Drummond GS, Manola T. Sn-protoporphyrin use in the management of hyperbilirubinemia in term newborns with direct Coombs-positive ABO incompatibility. Pediatrics 1988;81:485-497.
  55. Valaes T, Petmezaki S, Henschke C. Control of jaundice in preterm newborns by an inhibitor of bilirubin production: Studies with tin-mesoporphyrin. Pediatrics 1994;93:1-11.
  56. Kappas A, Drummond GS, Henschke C. Direct comparison of Sn-mesoporphyrin, an inhibitor of bilirubin production, and phototherapy in controlling hyperbilirubinemia in term and near-term newborns. Pediatrics 1995;95:468-474.
  57. McDonagh AF, Palma LA. Tin-protoporphyrin: A potent photosensitizer of bilirubin destruction. Photochem Photobiol 1985;42:261-264.
  58. Suresh GK, Martin CL. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates. Cochrane Library 2003;. Accessed on November 21, 2003. URL: http://www.nichd.nih.gov/cochraneneonatal.
  59. Cremer RJ, Perryman PW, Richards DH. Influence of light on the hyperbilirubinemia of infants. Lancet 1958;1094-1097.
  60. Ennever JF. Blue light, green light, white light, more light: Treatment of neonatal jaundice. Clin Perinatol 1990;17:467-481.
  61. Vreman HJ, Wong RJ, Stevenson DK. Light-emitting diodes: A novel light source for phototherapy. Pediatr Res 1998;44:804-809.
  62. MacMahon JR, Stevenson DK, Oski FA. Management of hyperbilirubinemia. In Avery's Diseases of the Newborn, eds Taeusch HW, Ballard RA. Philadelphia, PA: Saunders; 1998. 1033-1042.
  63. Shinwell ES, Sciaky V, Karplus M. Effect of position changing on bilirubin levels during phototherapy. J Perinatol 2002;22:226-229.
  64. Tan KL. Decreased response to phototherapy for neonatal jaundice in breast-fed infants. Arch Pediatr Adolesc Med 1998;152:1187-1190.
  65. Yao AC, Martinussen M, Johansen M. Phototherapy-associated changes in mesenteric blood flow response to feeding in term neonates. J Pediatr 1994;124:309-312.
  66. Tan KL. Comparison of the efficacy of fiberoptic and conventional phototherapy for neonatal hyperbilirubinemia. J Pediatr 1994;125:607-612.
  67. van Kaam AHIC, van Beek RHT, Vergunst-van Keulen JG. Fibre optic versus conventional phototherapy for hyperbilirubinaemia in preterm infants. Eur J Pediatr 1998;157:132-137.
  68. Mills JF, Tudehope D. Fibreoptic phototherapy for neonatal jaundice. Cochrane Library 2001;. Accessed on November 21, 2003. URL: http://www.nichd.nih.gov/cochraneneonatal.
  69. Seidman DS, Moise J, Ergaz Z. A new blue light-emitting phototherapy device: A prospective randomized controlled study. J Pediatr 2000;136:771-774.
  70. Sideman DS, Moise J, Ergaz Z. A prospective randomized controlled study of phototherapy using blue and blue-green light-emitting devices, and conventional halogen-quartz phototherapy. J Perinatol 2003;23:123-127.
  71. Kaplan M. Genetic interactions in the pathogenesis of neonatal hyperbilirubinemia: Gilbert's syndrome and glucose-6-phosphate dehydrogenase deficiency. J Perinatol 2001;21:s30-s34.
  72. Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.